FTRE Fortrea Holdings Inc. stock chart & analysis
Conviction 20HealthcareScan · Fri, Nov 6, 2026Fortrea Holdings Inc. (FTRE) closed at $21.96 (+7.33%) on Nov 6, 2026. Price is above its 50-day and above its 200-day moving average. RSI(14) 51, RS Rating 96, -16.3% from its 52-week high, +27.0% year to date. Sector: Healthcare · Services-Medical Laboratories.
Financials as of Wed, Sep 30, 2026 · quarterly.
FTRE technical analysis
Trend
FTRE is in an uptrend: price is above the 50-day, which is above the 200-day moving average. It closed 6.8% above the 50-day ($20.51) and 38.6% above the 200-day ($15.80). ADX(14) at 31 points to a strong, established trend. It meets 8 of 8 trend-template criteria.
Momentum
RSI(14) is 51, in the bullish half of its range. MACD crossed below its signal line 5 sessions ago. Its RS Rating of 96 puts its weighted 12-month performance ahead of about 96% of the US market.
Volume and volatility
Volume on the latest session ran 0.7× its 20-day average. It trades about $47.8M a day on average. ATR(14) is $1.47, 6.7% of price — its typical daily range. Chaikin Money Flow (0.11) shows accumulation.
Key levels
The chart pattern's support is $19.15 and its resistance $25.50. The 52-week range is $8.55 to $26.16; price is 16.3% below the high and 156.3% above the low. The VWAP anchored at the 52-week high is $22.32, above price.
Performance
FTRE returned +2.9% (1 week), +7.6% (1 month), +15.4% (3 months), +42.0% (6 months), +83.4% (1 year), +27.0% (year to date).
About Fortrea Holdings Inc.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion.
Services-Medical Laboratories · Listed 2023 · 14,000 employees
Congress activity
Disclosed STOCK Act trades in FTRE · 1 recent
| Member | Side | Amount | Traded | Filed | PTR |
|---|---|---|---|---|---|
 James French Hill house · AR · traded 2025-06-23 | Sell | $1K–$15K | 2025-06-23 | 2025-07-24 |
Insider activity
SEC Form 4 transactions in FTRE · open-market 6 sells
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Morais Mark A. Chief Operating Officer · Common Stock · 2026-08-19 | Sell | 4.89K | $89K | 2026-08-19 | 2026-08-19 |
Morais Mark A. Chief Operating Officer · Restricted Stock Unit · 2026-08-18 | Exercise | 11.31K | — | 2026-08-18 | 2026-08-19 |
Morais Mark A. Chief Operating Officer · Common Stock · 2026-08-18 | Exercise | 11.31K | — | 2026-08-18 | 2026-08-19 |
Thakral Anshul Chief Executive Officer · Common Stock · 2026-08-06 | Sell | 55.88K | $1.0M | 2026-08-06 | 2026-08-07 |
Thakral Anshul Chief Executive Officer · Common Stock · 2026-08-06 | Sell | 55.98K | $1.0M | 2026-08-06 | 2026-08-07 |
SANDERS MACHELLE Director · Common Stock · 2026-08-03 | Sell | 9.7K | $175K | 2026-08-03 | 2026-08-05 |
Smith David Ross Interim CFO · Restricted Stock Unit · 2026-08-03 | Grant | 15.84K | — | 2026-08-03 | 2026-08-05 |
Smith David Ross Director · Common Stock · 2026-07-20 | Exercise | 6.6K | — | 2026-07-20 | 2026-07-27 |
Mcconnell Jill G. Chief Financial Officer · Common Stock · 2026-06-02 | Sell | 4.87K | $75K | 2026-06-02 | 2026-06-03 |
Morais Mark A. Chief Operating Officer · Common Stock · 2026-06-02 | Sell | 4.87K | $75K | 2026-06-02 | 2026-06-03 |
SEC filings
EDGAR filings in FTRE · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.
Start free — 7-day trial, no card →Free daily signals by email. Top 3 setups per lane after every close. No account needed.
Unsubscribe anytime · Privacy
Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.